StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30742% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Travere Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $591.33M, up 77.1% year over year. For fiscal 2026 it was $490.73M, up 110.5% from the year before. Over ten years it grew 17.3% a year on average. The highest annual figure on record is $490.73M in fiscal 2026.

Annual revenue

PeriodPeriod endValueChange
FY2026Dec 31, 2025$490.73M+110.5%
FY2025Dec 31, 2024$233.18M+60.5%
FY2024Dec 31, 2023$145.24M+32.7%
FY2023Dec 31, 2022$109.46M-17.0%
FY2022Dec 31, 2021$131.84M-33.5%
FY2021Dec 31, 2020$198.32M+13.1%
FY2020Dec 31, 2019$175.34M+6.8%
FY2019Dec 31, 2018$164.25M+6.0%
FY2018Dec 31, 2017$154.94M+16.0%
FY2017Dec 31, 2016$133.59M+33.7%
FY2016Dec 31, 2015$99.89M+254.2%
FY2015Dec 31, 2014$28.20M–
FY2014Dec 31, 2013$0–
FY2012Feb 29, 2012$0–
FY2011Feb 28, 2011$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$169.58M+48.2%
Q1 FY2027Mar 31, 2026$127.20M+55.6%
Q4 FY2026Dec 31, 2025$129.69M+73.4%
Q3 FY2026Sep 30, 2025$164.86M+162.1%
Q2 FY2026Jun 30, 2025$114.45M+111.5%
Q1 FY2026Mar 31, 2025$81.73M+97.5%
Q4 FY2025Dec 31, 2024$74.79M+66.0%
Q3 FY2025Sep 30, 2024$62.90M+69.6%
Q2 FY2025Jun 30, 2024$54.12M+68.1%
Q1 FY2025Mar 31, 2024$41.37M+33.9%
Q4 FY2024Dec 31, 2023$45.06M+53.6%
Q3 FY2024Sep 30, 2023$37.10M+32.1%
Q2 FY2024Jun 30, 2023$32.20M+12.4%
Q1 FY2024Mar 31, 2023$30.89M+31.9%
Q4 FY2023Dec 31, 2022$29.34M-48.8%
Q3 FY2023Sep 30, 2022$28.08M-58.8%
Q2 FY2023Jun 30, 2022$28.63M-47.6%
Q1 FY2023Mar 31, 2022$23.41M-50.6%
Q4 FY2022Dec 31, 2021$57.25M+12.3%
Q3 FY2022Sep 30, 2021$68.22M+33.4%
Q2 FY2022Jun 30, 2021$54.62M+12.8%
Q1 FY2022Mar 31, 2021$47.41M-0.8%
Q4 FY2021Dec 31, 2020$50.98M+9.2%
Q3 FY2021Sep 30, 2020$51.14M+15.2%
Q2 FY2021Jun 30, 2020$48.43M+8.3%
Q1 FY2021Mar 31, 2020$47.77M+20.7%
Q4 FY2020Dec 31, 2019$46.69M+6.7%
Q3 FY2020Sep 30, 2019$44.37M+9.0%
Q2 FY2020Jun 30, 2019$44.71M+8.2%
Q1 FY2020Mar 31, 2019$39.57M+3.0%
Q4 FY2019Dec 31, 2018$43.77M+3.8%
Q3 FY2019Sep 30, 2018$40.71M+0.9%
Q2 FY2019Jun 30, 2018$41.34M+6.5%
Q1 FY2019Mar 31, 2018$38.43M+14.3%
Q4 FY2018Dec 31, 2017$42.18M+13.0%
Q3 FY2018Sep 30, 2017$40.34M+18.8%
Q2 FY2018Jun 30, 2017$38.80M–
Q1 FY2018Mar 31, 2017$33.62M–
Q4 FY2017Dec 31, 2016$37.33M–
Q3 FY2017Sep 30, 2016$33.95M–

More Travere Therapeutics figures

See a number that looks wrong?